Skip to main content

Table 4 Logistic regression of urinary Ln(β2-MG/uCr) with response to steroid treatment in validation cohort A and B

From: New risk score for predicting steroid resistance in patients with focal segmental glomerulosclerosis or minimal change disease

 OR (95% CI)aOR (95% CI)bOR (95% CI)c
Validation cohort A1.62 (1.18–2.21)#1.58 (1.15–2.15)#1.51 (1.09–2.08)*
Validation cohort B1.96 (0.54–7.25)2.32 (0.63–8.52)1.51 (0.36–6.38)
  1. Validation cohort A: FSGS + MCD (N = 157)
  2. Validation cohort B: MN (N = 59)
  3. Renal outcome defined as no response to therapy
  4. β2-microglobulin; uCr: urinary creatinine
  5. a Adjusted by age, gender and clinical parameters (eGFR)
  6. b Adjusted by age, gender and pathological parameters (global sclerosis, segmental sclerosis, interstitial fibrosis, inflammatory cell infiltration and tubular atrophy)
  7. c Adjusted by age, gender, clinical parameters (eGFR) and pathological parameters (global sclerosis, segmental sclerosis, interstitial fibrosis, inflammatory cell infiltration and tubular atrophy)
  8. *P < 0.05, #P < 0.01